Molecular structure of (R,S)-Equol, CAS Number: 94105-90-5
(R,S)-Equol (CAS 94105-90-5)
See product citations (2)
Application:
(R,S)-Equol is an inhibitor that targets the MEK/ERK/p90RSK/activator protein-1 signalling pathway
CAS Number:
94105-90-5
Purity:
≥98%
Molecular Weight:
242.27
Molecular Formula:
C15H14O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
(R,S)-Equol is a flavonoid. Racemic mixture. This is a metabolite that can be produced from soy phytoestrogen daidzein from gut microflora. (R,S)-Equol inhibits 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 signalling pathway. Functions as a DHT blocker. Preferentially activates ER beta (estrogen receptor beta). As a metabolite of soy isoflavones, equol is considered a phytoestrogen — a plant-derived compound with estrogen-like activity.
(R,S)-Equol (CAS 94105-90-5) References
- Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. | Lund, TD., et al. 2004. Biol Reprod. 70: 1188-95. PMID: 14681200
- Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. | Muthyala, RS., et al. 2004. Bioorg Med Chem. 12: 1559-67. PMID: 15018930
- Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. | Akaza, H., et al. 2004. Jpn J Clin Oncol. 34: 86-9. PMID: 15067102
- Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. | Mueller, SO., et al. 2004. Toxicol Sci. 80: 14-25. PMID: 15084758
- Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women. | Frankenfeld, CL., et al. 2004. Cancer Epidemiol Biomarkers Prev. 13: 1156-62. PMID: 15247126
- High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart. | Frankenfeld, CL., et al. 2005. Br J Nutr. 94: 873-6. PMID: 16351761
- Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. | Kang, NJ., et al. 2007. J Biol Chem. 282: 32856-66. PMID: 17724030
- Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights. | Jackman, KA., et al. 2007. Curr Med Chem. 14: 2824-30. PMID: 18045128
- Discovery of an S-equol rich food stinky tofu, a traditional fermented soy product in Taiwan. | Abiru, Y., et al. 2012. Int J Food Sci Nutr. 63: 964-70. PMID: 22594820
- The influence of microbial isoflavonoid specific metabolites on platelets and transition metals iron and copper. | Migkos, T., et al. 2019. Phytomedicine. 62: 152974. PMID: 31181402
Activator of:
ER beta.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
(R,S)-Equol, 5 mg | sc-202307 | 5 mg | $32.00 | |||
(R,S)-Equol, 25 mg | sc-202307A | 25 mg | $142.00 |